ESR2 and melanoma: A definite comprehension of the molecular pathways underlying the ERβ effectiveness in mutated NRAS cells would dissect the direct and indirect mechanisms, exploiting the ERβ antitumor potential possibly associated with the different mutations underlying melanoma.